Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)

por Wiegel, Thomas, Albers, Peter, Bartkowiak, Detlef, Bussar-Maatz, Roswitha, Härter, Martin, Kristiansen, Glen, Martus, Peter, Wellek, Stefan, Schmidberger, Heinz, Grozinger, Klaus, Renner, Peter, Schneider, Fried, Burmester, Martin, Stöckle, Michael
Publicado 2020

Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial

por Albers, Peter, Wiegel, Thomas, Schmidberger, Heinz, Bussar-Maatz, Roswitha, Härter, Martin, Kristiansen, Glen, Martus, Peter, Meisner, Christoph, Wellek, Stefan, Grozinger, Klaus, Renner, Peter, Burmester, Martin, Schneider, Fried, Stöckle, Michael
Publicado 2020

Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten’s to the Letter to the editor Re: results of a randomized trial of treatment modal...

por Wiegel, Thomas, Albers, Peter, Bartkowiak, Detlef, Bussar-Maatz, Roswitha, Härter, Martin, Kristiansen, Glen, Martus, Peter, Wellek, Stefan, Schmidberger, Heinz, Grozinger, Klaus, Renner, Peter, Schneider, Fried, Burmester, Martin, Stöckle, Michael
Publicado 2021